Kyntra Bio (KYNB)
NASDAQ:KYNB
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 6.44M | $ 29.62M | $ 46.80M | $ 140.73M | $ 235.31M |
| Gross Profit | $ 0.00 | $ 14.06M | $ 42.84M | $ 120.45M | $ -213.88M |
| Operating Income | $ -45.90M | $ -150.42M | $ -322.72M | $ -301.02M | $ -288.53M |
| EBITDA | $ -45.90M | $ -142.43M | $ -305.20M | $ -282.82M | $ -333.72M |
| Net Income | $ 183.45M | $ -47.58M | $ -284.23M | $ -293.65M | $ -290.02M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 88.98M | $ 50.48M | $ 235.59M | $ 422.01M | $ 405.19M |
| Total Assets | $ 119.59M | $ 214.53M | $ 423.53M | $ 610.09M | $ 773.82M |
| Total Debt | $ 0.00 | $ 90.17M | $ 170.46M | $ 89.89M | $ 99.72M |
| Net Debt | $ -47.87M | $ 39.69M | $ 56.77M | $ -65.81M | $ -71.50M |
| Total Liabilities | $ 115.12M | $ 398.16M | $ 585.73M | $ 611.57M | $ 544.71M |
| Stockholders' Equity | $ 4.47M | $ -225.60M | $ -204.17M | $ -21.45M | $ 209.15M |
| Cash Flow | |||||
| Free Cash Flow | $ -4.81M | $ -138.26M | $ -317.54M | $ -184.67M | $ -112.42M |
| Operating Cash Flow | $ -4.77M | $ -138.00M | $ -315.02M | $ -145.93M | $ -82.23M |
| Investing Cash Flow | $ 35.42M | $ 125.99M | $ 153.66M | $ 89.12M | $ -426.97M |
| Financing Cash Flow | $ -86.03M | $ -255.00K | $ 122.75M | $ 46.78M | $ -563.00K |